Treatment-Resistant Depression (TRD)Depressive DisordersHealthy VolunteersKetaminePlacebo

Ketamine induces multiple individually distinct whole-brain functional connectivity signatures

This single-blind placebo-controlled study (n=40) investigated the neural and behavioral effects of acute ketamine in healthy participants. Results revealed robust inter-individual variability in both neural and behavioral responses to ketamine, with data-driven individual symptom variation mapping onto distinct neural gradients. These findings emphasize the need to consider individual variation in response to ketamine and suggest potential implications for developing precise pharmacological biomarkers in psychiatry.

Authors

  • Erich Seifritz
  • Franz Vollenweider
  • Katrin Preller

Published

eLife
individual Study

Abstract

Background

Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine’s molecular mechanisms connect to its neural and behavioral effects.

Methods

We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition. 40 healthy participants received acute ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr). We quantified resting-state functional connectivity via data-driven global brain connectivity and related it to individual ketamine-induced symptom variation and cortical gene expression targets.

Results

We found that: (i) both the neural and behavioral effects of acute ketamine are multi-dimensional, reflecting robust inter-individual variability; (ii) ketamine’s data-driven principal neural gradient effect matched somatostatin (SST) and parvalbumin (PVALB) cortical gene expression patterns in humans, while the mean effect did not; and (iii) behavioral data-driven individual symptom variation mapped onto distinct neural gradients of ketamine, which were resolvable at the single-subject level.

Conclusions

These results highlight the importance of considering individual behavioral and neural variation in response to ketamine. They also have implications for the development of individually precise pharmacological biomarkers for treatment selection in psychiatry.

Available with Blossom Pro

Research Summary of 'Ketamine induces multiple individually distinct whole-brain functional connectivity signatures'

Introduction

Earlier whole-brain studies indicate that ketamine produces robust, brain-wide alterations in functional connectivity, including increased global brain connectivity (GBC) in prefrontal cortex and shifts from cortical- to subcortically-centred states. However, those group-average approaches can obscure meaningful inter-individual differences, and prior findings have been inconsistent across timepoints and samples. The authors note that data-driven multivariate methods such as principal component analysis (PCA) can reveal both group-level and individual-level axes of variation and therefore are well suited to test whether ketamine's effects are uni-dimensional (a single uniform pattern) or multi-dimensional (multiple distinct patterns across individuals).

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (21)

Papers cited by this study that are also in Blossom

Ketamine Treatment and Global Brain Connectivity in Major Depression

Abdallah, C. G., Averill, L. A., Collins, K. A. et al. · Neuropsychopharmacology (2016)

2 cited
Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors

De Gregorio, D., Posa, L., Ochoa-Sanchez, R. et al. · Pharmacological Research (2016)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)

Ketamine-induced modulation of the thalamo-cortical network in healthy volunteers as a model for schizophrenia

Höflich, A., Hahn, A., Küblböck, M. et al. · International Journal of Neuropsychopharmacology (2015)

109 cited
Show all 21 references
Ketamine: A Paradigm Shift for Depression Research and Treatment

Abdallah, C. G., Charney, D. S., Duman, R. S. et al. · Neuron (2019)

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)

The pharmacology of lysergic acid diethylamide: a review

Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)

The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation

Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)

Psilocybin induces time-dependent changes in global functional connectivity: Psi-induced changes in brain connectivity

Preller, K. H., Burt, J. B., Adkinson, B. et al. · Biological Psychiatry (2020)

Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions

Riva-Posse, P., Reiff, C. M., Edwards, J. A. et al. · Journal of Affective Disorders (2018)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Cited By (1)

Papers in Blossom that reference this study

Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study

Mallevays, M., Fuet, L., Danon, M. et al. · MedRvix (2026)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.